Story perspectives

Targeted Immunotherapies Double Survival, Spur Remission Without Surgery

6/6/2026

Summary

Story summary

Recent trials show personalized immunotherapy and targeted drugs can achieve remission or double survival without chemo or surgery.
PD-1 inhibitor immunotherapy caused complete remission in dMMR or MSI-H rectal cancer, making surgery potentially unnecessary.
A UCLA-led trial found daraxonrasib doubled median survival for pancreatic cancer from 6.5 to about 13 months.
An mRNA-vaccine plus Keytruda kept 69% of melanoma patients cancer-free after five years, halving recurrence risk versus Keytruda alone.

1 of 1

Story summary

Recent trials show personalized immunotherapy and targeted drugs can achieve remission or double survival without chemo or surgery.
PD-1 inhibitor immunotherapy caused complete remission in dMMR or MSI-H rectal cancer, making surgery potentially unnecessary.
A UCLA-led trial found daraxonrasib doubled median survival for pancreatic cancer from 6.5 to about 13 months.
An mRNA-vaccine plus Keytruda kept 69% of melanoma patients cancer-free after five years, halving recurrence risk versus Keytruda alone.